Curaleaf Joins Founding Group of New British Medical Cannabis Association
LONDON – Curaleaf International, the European and international operating division of Curaleaf Holdings, Inc., has joined a coalition of licensed operators to establish the Cannabis Based Medicines Association (CBMA) – the first British trade organization devoted exclusively to prescribed Cannabis products. Announced following the group’s official launch in London, the association brings Curaleaf together with British cultivator Glass Pharms and specialist provider Wellford Clinics as founding members.
Unlike broader industry groups in Britain that include advocacy organizations, wellness brands, and patient coalitions, the new association restricts voting rights strictly to companies holding British regulatory licenses. Its founding manifesto, titled Towards Mainstream Healthcare, outlines five core goals that prioritize patient safety, clinical evidence, and stricter adherence to existing prescribing rules. Under its internal governance, member companies will divide their work across three committees covering regulatory compliance, institutional outreach, and clinical data collection.
The formation of the group arrives eight years after Britain legalized Cannabis products for medical prescriptions in November 2018. While private clinic prescriptions have expanded steadily since then, the sector has drawn closer scrutiny from health regulators and lawmakers over clinical consistency and marketing practices. The Advisory Council on the Misuse of Drugs (ACMD) is scheduled to complete a formal review of the British medical Cannabis framework by the end of 2026, creating an urgent window for licensed businesses to present unified operational standards.
Ahead of that review, the association has already begun engaging British oversight bodies. The group confirmed plans to participate in the All Party Parliamentary Group for Medical Cannabis under Prescription and recently joined the Medical Cannabis Clinicians Society in writing to Professor Henrietta Hughes, the Patient Safety Commissioner for England, regarding prescribing safeguards. Still, the governance structure has prompted cautious feedback from patient advocates. In a public response, the advocacy group PatientsCann UK welcomed the emphasis on clinical safety but noted that reserving voting power for commercial license holders leaves patients without a formal voice in setting industry rules.
Wrapping up, the launch reflects an accelerating effort by established European medical operators to separate pharmaceutical style Cannabis programs from wider consumer hemp and recreational debates. By creating a tighter, license-only trade body, companies like Curaleaf International are seeking to protect their clinical credibility and lower regulatory friction before government advisors finalize new recommendations. In European medical markets, long term commercial stability increasingly favors operators that can demonstrate rigorous clinical governance, measurable patient outcomes, and clear alignment with national health authorities.






































